The SPIN 2022 Congress was held between 06–08 July 2022 in Paris, France. The congress was dedicated to inflammatory skin diseases and provided a comprehensive overview of the state-of-the-art and insights into its clinical course and innovative pathogenesis-based treatments.
The revolutionary development of small molecules and biologics in the treatment of atopic dermatitis has changed clinical practice. Furthermore, new findings on the clinical relevance of biomarkers may help move towards personalised medicine in the future: Carriers of a filaggrin gene variant proved to have a high risk for bacterial infections.
The innovations in the management of psoriasis are a continuous evolution of more effective and safe treatments targeted at pathogenesis-relevant aspects with little collateral damage concerning side effects. Insights into the relevance of clear skin for long-term sustainable control of disease and comorbidities have changed clinical practice. Furthermore, research on biomarkers provides future opportunities for personalised care, such as drug levels and HLA-Cw6 status.
The management of patients with vitiligo, hidradenitis suppurativa, and alopecia areata was limited to a few treatments with poor outcomes until recently. Now, it is clear that the innovations in therapeutic possibilities of inflammatory skin diseases also provide a new future perspective for patients suffering from these conditions.
Peter CM van de Kerkhof
Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was a board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.
Conflict of Interest Statement:
Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma, Sandoz, Mitsubishi Tanabe, Bristol Meyer Squibb, UCB, Dermavant.
Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.
« Therapies for atopic dermatitis: still moving forward Next Article
Lifelong benefits of statin therapy »
Table of Contents: SPIN 2022
Letter from the Editor
SPIN 2022 Highlights Podcast
IMIDs in Adults and Children: New Developments
Therapies for atopic dermatitis: still moving forward
Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant
Men on biologics report fewer adverse events than women
Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs
Psoriasis: The Beat Goes On
Systemic treatment for psoriasis: what is on the horizon?
Topical therapy in psoriasis: an important partner in combination therapy
GPP flares: pronounced undertreatment is common
IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas
Psoriasis patients see great benefit in achieving complete skin clearance
The Future Is Bright for Vitiligo
Predilection sites for skin signs of vitiligo disease activity determined
Where Are We Now in Hidradenitis Suppurativa
IHS4 better suited as an outcome measure in HS trials?
New treatments for HS: IL-17 inhibitors next in practice?
New Treatment Options in Alopecia Areata
Alopecia areata: light at the end of the tunnel
Alopecia areata pathogenesis: known genetic background, unknown environmental triggers
Best of the Posters
Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab
Dose tapering in psoriasis is associated with a low relapse rate
Plaque psoriasis – Efficacy of guselkumab
Biologic psoriasis treatment and COVID-19 risk: Contradictory results